BridgeBio Oncology Therapeutics, Inc. Logo

BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma developing inhibitors for genetically driven cancers.

BBOT | US

Overview

Corporate Details

ISIN(s):
KYG4444H1011
LEI:
Country:
United States of America
Address:
256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops a pipeline of novel, bioavailable small molecule inhibitors designed to treat patients with RAS-dependent cancers and other malignancies with clear genetic drivers. Its core strategy centers on inhibiting active RAS, aiming to create transformative medicines that advance beyond current therapeutic approaches. BBOT was launched to accelerate the development of its parent company's precision oncology portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Clearmind Medicine Inc. Logo
Clinical-stage psychedelic pharma firm developing treatments for Alcohol Use Disorder.
United States of America
CMND
Clearside Biomedical, Inc. Logo
Biopharmaceutical firm with an FDA-approved microinjector for back-of-the-eye delivery.
United States of America
CLSD
Clene Inc. Logo
A clinical-stage biopharma developing nanotherapeutics for neurodegenerative diseases.
United States of America
CLNN
CMG Pharmaceutical Co., Ltd. Logo
A pharmaceutical firm specializing in Oral Thin Film drug delivery technology.
South Korea
058820
CNS Pharmaceuticals, Inc. Logo
Develops anti-cancer drug candidates for cancers of the brain and nervous system.
United States of America
CNSP
Cocrystal Pharma, Inc. Logo
Clinical-stage biotech developing antiviral drugs for serious and chronic viral diseases.
United States of America
COCP
Co-Diagnostics, Inc. Logo
A molecular diagnostics company that develops and markets advanced PCR technologies.
United States of America
CODX
co.don AG Logo
Develops autologous cell therapies for regenerative treatment of cartilage defects.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Biopharmaceutical company developing cell therapy platforms for cancer and other diseases.
United States of America
COEP
Cogent Biosciences, Inc. Logo
A clinical-stage biotech company developing precision therapies for genetic diseases.
United States of America
COGT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.